These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 14715850

  • 1. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [Abstract] [Full Text] [Related]

  • 2. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [Abstract] [Full Text] [Related]

  • 3. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [Abstract] [Full Text] [Related]

  • 5. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [Abstract] [Full Text] [Related]

  • 6. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 7. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M.
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [Abstract] [Full Text] [Related]

  • 8. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [Abstract] [Full Text] [Related]

  • 9. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [Abstract] [Full Text] [Related]

  • 10. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [Abstract] [Full Text] [Related]

  • 11. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 12. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Phielix E, Brehm A, Bernroider E, Krssak M, Anderwald CH, Krebs M, Schmid AI, Nowotny P, Roden M.
    Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
    [Abstract] [Full Text] [Related]

  • 13. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
    Ye JM, Frangioudakis G, Iglesias MA, Furler SM, Ellis B, Dzamko N, Cooney GJ, Kraegen EW.
    Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
    [Abstract] [Full Text] [Related]

  • 14. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
    Bajaj M, Baig R, Suraamornkul S, Hardies LJ, Coletta DK, Cline GW, Monroy A, Koul S, Sriwijitkamol A, Musi N, Shulman GI, DeFronzo RA.
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1916-23. PubMed ID: 20157197
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
    Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.
    Diabetologia; 2009 Apr; 52(4):723-32. PubMed ID: 19169664
    [Abstract] [Full Text] [Related]

  • 16. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K.
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [Abstract] [Full Text] [Related]

  • 17. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [Abstract] [Full Text] [Related]

  • 18. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
    Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E.
    Diabetes Care; 2008 Jan; 31(1):121-7. PubMed ID: 17909084
    [Abstract] [Full Text] [Related]

  • 19. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M, H6E-MC-GLAT study group.
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [Abstract] [Full Text] [Related]

  • 20. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
    Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M.
    Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.